The House Judiciary Committee yesterday approved by voice vote the Creating and Restoring Equal Access to Equivalent Samples Act (H.R. 965), AHA-supported legislation that would allow generic drug manufacturers facing certain anticompetitive delay tactics to bring an action in federal court for injunctive relief. Previously passed by the Energy and Commerce Committee, the bill could next move to the floor.
 
In other action yesterday, the Judiciary Committee approved bipartisan bills to strengthen the Federal Trade Commission’s ability to challenge anticompetitive pay-for-delay agreements in court (H.R. 2375); reduce incentives for brand name drug makers to interfere with the regulatory approval of generics and biosimilars (H.R. 2374); and require the FTC to study competition in the drug supply chain (H.R. 2376).

Related News Articles

Headline
Reps. Bradley Schneider, D-Ill., Don Bacon, R-Neb., and Abby Finkenauer, D-Iowa, yesterday introduced a House companion to AHA-supported legislation that would…
Headline
The House Budget Committee today held a hearing on the Congressional Budget Office’s recent report on key design components and considerations for policymakers…
Headline
Sens. Bill Cassidy, R-La., Michael Bennet, D-Colo., Todd Young, R-Ind., Maggie Hassan, D-N.H., Lisa Murkowski, R-Alaska, and Tom Carper, D-Del., today…
Headline
House Energy and Commerce Committee leaders today released a discussion draft of bipartisan legislation to address surprise medical bills.
Headline
The House of Representatives yesterday voted 230-183 to pass AHA-supported legislation (H.R. 986) that would rescind the administration’s latest guidance for…
Headline
The House Appropriations Committee yesterday voted 30-23 to approve with changes legislation that would provide $189.9 billion in base discretionary funding…